Role of Serum Creatinine Levels in Prognostic Risk Stratification of Prostate Cancer Patients

ACDEFG 1 Xingbo Gu
BCDEF 1 Jiaojiao Wu
AD 2 Xuefeidan Liu
BCDF 1 Yun Hong
AD 3 Yaoxi Wu
AD 1 Ye Tian

Corresponding Authors: Xingbo Gu, e-mail: hljgxb@gmail.com, Ye Tian, e-mail: tianyetongji@163.com

Financial support: This work was supported by the Hainan Provincial Natural Science Foundation of China (no. 822QN323) and the Startup Foundation for Advanced Talents of Hainan Medical University (no. XRC202114)

Conflict of interest: None declared

Background: Studies on the relationship between serum creatinine and the prognosis of prostate cancer have been very limited. The aim of this study was to investigate the role of serum creatinine in the prognostic risk stratification of patients with prostate cancer.

Material/Methods: We identified 1134 eligible patients from the “Prostate Cancer Data Set” in the National Clinical Medical Science Data Center. Patients with prostate cancer were divided high- and low-risk prognostic groups according to prostate-specific antigen levels and Gleason scores and were divided into 5 groups according to serum creatinine quintile: Q1 (<70.1 umol/L), Q2 (70.1-76.8 umol/L), Q3 (76.8-83.4 umol/L), Q4 (83.4-92.1 umol/L), and Q5 (>92.1 umol/L). Multivariate logistic regression and a multiple restricted cubic spline method were used to evaluate the relationship between serum creatinine level and the level of prostate cancer prognostic risk.

Results: Of the 1134 patients with prostate cancer, 134 (11.8%) had a high-risk prognosis. Compared with the Q2 group (the reference group), the lowest serum creatinine levels in the Q1 group and the highest serum creatinine levels in groups Q5, Q3, and Q4 were associated with a high-risk prognosis, and this association remained significant after adjusting for confounders. The multiple restricted cubic spline regression model showed the relationship between serum creatinine level and high-risk prognosis was U-shaped.

Conclusions: Serum creatinine level was an independent predictor of high-risk prognosis. Controlling serum creatinine levels between 70.1 and 76.8 umol/L in patients with prostatic cancer may benefit the prognosis of patients with prostatic cancer.

Keywords: Creatinine • Prostatic Neoplasms • Prognosis • Risk Factors

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/937100
Background

Prostate cancer is a common genitourinary malignancy in men, and it is the second most common cancer worldwide and the fifth leading cause of cancer-related death in this sex [1]. According to the Centers for Disease Control, African Americans have the highest incidence of prostate cancer, followed by Europeans, and Asian ethnic groups have the lowest [2]. The incidence of prostate cancer in China has been increasing significantly in recent years. In 2015, the incidence of prostate cancer in China ranked sixth among male malignant tumors, and the death rate among male malignant tumors ranked tenth [3,4].

Early prostate cancer may not show associated symptoms, as its incubation period is imperceptible in development [5]. Most patients with prostate cancer are in the middle and advanced stages at the time of diagnosis, resulting in the overall prognosis of patients with prostate cancer in China being much lower than that in Western Europe and the United States [6]. Treatment modalities also vary widely among patients with different types of prostate cancer [7]. Patients with early, low-risk prostate cancer can achieve good therapeutic effects by radical surgery or radical radiotherapy and can even be cured [8]. However, patients with advanced, high-risk prostate cancer generally chose palliative treatment based on androgen deprivation therapy to prolong their survival [9]. The 2020 European Urological Association Prostate Cancer Diagnosis and Treatment Guidelines and the National Comprehensive Cancer Network Prostate Cancer Clinical Practice Guidelines point out that patients with different types of prostate cancer have different treatment modalities and also have different prognoses [10,11].

Serum creatinine is a metabolite of human muscle, which is closely related to the total amount of muscle in the body. The determination of serum creatinine concentration is an effective indicator for evaluating the glomerular filtration rate (GFR), which is important for clinical diagnosis and treatment [12]. In recent years, studies have shown that serum creatinine levels are correlated with serum-free prostate-specific antigen (PSA) levels, and changes in renal function can affect PSA [13]. Moreover, serum creatinine has been identified to be of clinical value in the diagnosis or prognosis of various neoplastic diseases, such as pancreatic cancer, vulvar cancer, and epithelial ovarian cancer [14-17].

At present, accurately distinguishing high-risk from low-risk patients in the clinical work of prostate cancer is one of the intractable problems facing clinicians and has an important impact on the treatment and prognostic measures of patients. However, studies on the prognostic role of serum creatinine in patients with prostate cancer are relatively scarce. Therefore, the primary aim of this study was to investigate the role of serum creatinine levels in the prognostic risk stratification of patients with prostate cancer to provide direction for clinical decision-making.

Material and Methods

The data of this study were obtained from the “Prostate Cancer Data Set” in the National Population Health Data Center (https://www.ncmi.cn/), which is a scientific data warehouse established by a number of scientific research institutions, universities, and hospitals in China that has stored more than 15,000 datasets to date. The “Prostate Cancer Data Set” (https://www.ncmi.cn/phda/dataDetails.do?id=CSTR:A0006.11.A0005.201905.000531) includes the data of prostate cancer patients collected by the Chinese PLA General Hospital from January 1, 2010, to December 31, 2019. The original data were retrieved from the Chinese PLA General Hospital electronic medical record system and cleaned by the 301 Hospital's data engineers. This dataset is freely available and includes data on 3000 patients (1406 with benign prostatic hyperplasia and 1134 with prostate cancer) hospitalized in the Chinese PLA General Hospital. We signed a data use agreement and obtained approval from the National Clinical Medical Science Data Center (the Chinese PLA General Hospital).

The criteria for exclusion were (1) patients with benign prostatic hyperplasia (n=1406); (2) patients with a missing Gleason score (n=524); (3) patients with a total missing PSA (n=226). Finally, a total of 1134 patients with prostate cancer met the analysis requirements of this study (Figure 1 shows the flowchart of patients’ inclusion and exclusion).

The prognostic risk of patients was classified according to the D'Amico risk classification of the EAU guidelines [18]. According to the Gleason score and total PSA, patients with a Gleason score ≥8 and total PSA ≥20 ng/mL were included in the high-risk prostate cancer group, while the remaining patients were included in the low-risk prostate cancer group[19]. After grouping, there were 134 patients in the high-risk group and 1000 patients in the low-risk group. According to the serum creatinine level quintiles, the patients were divided into the following 5 groups: Q1 (<70.1 umol/L), Q2 (70.1-76.8 umol/L), Q3 (76.8-83.4 umol/L), Q4 (83.4-92.1 umol/L), and Q5 (>92.1 umol/L). Blood specimens of patients were collected and tested by a single laboratory within 15 days before a 12-core transperineal ultrasound-guided prostate biopsy was performed. Serum creatinine and other biochemical indexes were obtained from the results of blood tests.

Statistical Analysis

Continuous variables were expressed as mean±standard deviation, and the independent sample t test was used for...
Science Data Center. A data use agreement from the National Clinical Medical study did not require informed consent, and the authors ob participants or the use of personally identifiable information. The Data Center and did not involve interaction with human par

This study was based on publicly available data from the “Prostate Cancer Data Set” in the National Population Health Data Center and did not involve interaction with human participants or the use of personally identifiable information. The study did not require informed consent, and the authors obtained a data use agreement from the National Clinical Medical Science Data Center.

**Results**

Among the 1134 patients with prostate cancer, 134 (11.8%) had a high-risk prognosis. Their mean age was 66.9 years, with a standard deviation of 8.0 years; and the mean BMI was 24.9 kg/m², with a standard deviation of 3.0 kg/m². The results showed that the levels of alkaline phosphatase, creatine kinase isoenzyme, calcium, lactate dehydrogenase, and creatinine in the high-risk group were significantly higher than those in the low-risk group, while the levels of serum albumin, inorganic phosphorus, low-density lipoprotein cholesterol, and apolipoprotein A1 were higher in the low-risk group. The specific results are shown in Table 1.

In the unadjusted logistic regression model (Table 2), with serum creatinine group Q2 (70.1-76.8 umol/L) as the reference group, the rate of high-risk prostate cancer prognosis in Q1 (<70.1 umol/L), Q3 (76.8-83.4 umol/L), Q4 (83.4-92.1 umol/L), and Q5 (>92.1 umol/L) groups were statistically significant. After adjusting for age and BMI, the odds ratio (OR; 95% CI) of the rate of high-risk prostate cancer prognosis was 3.66 (1.75-7.67) and 3.76 (1.80-7.87) in the Q1 and Q5 groups, respectively, compared with the Q2 group. After adjusting for age, BMI, serum albumin, alkaline phosphatase, creatine kinase isoenzyme, calcium, inorganic phosphorus, lactate dehydrogenase, low-density lipoprotein cholesterol, and apolipoprotein A1 in model 3, the OR (95% CI) for the rate of high-risk prostate cancer prognosis was 5.46 (2.16-13.80) in the Q5 group, compared with the Q2 group, P<0.001. The curve fitting results showed that there was a U-shaped curve relationship between serum creatinine and a high-risk prognosis, and too low or too high serum creatinine levels increased the occurrence of a high-risk prognosis (Figure 2).

The results of the subgroup analysis showed that there was no significant heterogeneity between serum creatinine level and a high-risk prognosis (P-interaction >0.05) (Table 3).
Table 1. Characteristics of patients with prostate cancer.

| Characteristics               | All patients (n=1134) | Low-risk patients (n=1000) | High-risk patients (n=134) | P value |
|-------------------------------|-----------------------|---------------------------|----------------------------|---------|
| Age, years                    | 66.9 (8.0)            | 66.8 (8.1)                | 68.1 (7.5)                 | 0.083   |
| BMI (kg/m²)                   | 24.9 (3.0)            | 24.9 (3.0)                | 24.4 (2.8)                 | 0.078   |
| Serum albumin (g/L)           | 41.3 (3.1)            | 41.4 (3.0)                | 40.7 (3.5)                 | 0.007   |
| Alkaline phosphatase (U/L)    | 85.2 (156.6)          | 78.7 (142.2)              | 134.2 (233.4)              | 0.003   |
| Creatine kinase isoenzyme (U/L)| 15.4 (10.1)          | 15.2 (9.4)                | 17.5 (13.9)                | 0.032   |
| Serum sodium (mmol/L)         | 142.5 (2.3)           | 142.6 (2.3)               | 142.4 (2.6)                | 0.407   |
| Serum calcium (mmol/L)        | 2.3 (0.1)             | 2.3 (0.1)                 | 2.2 (0.1)                  | 0.012   |
| Serum chloride (mmol/L)       | 104.4 (3.1)           | 104.4 (3.0)               | 104.3 (3.5)                | 0.913   |
| Serum phosphorus (mmol/L)     | 1.1 (0.2)             | 1.2 (0.2)                 | 1.1 (0.2)                  | 0.047   |
| Lactic dehydrogenase (U/L)    | 35.9 (36.3)           | 154.4 (32.3)              | 167.2 (57)                 | 0.001   |
| Creatine kinase (U/L)         | 93.8 (52.5)           | 94.6 (52.4)               | 87.7 (53.4)                | 0.136   |
| Serum creatinine (μmol/L)     | 83.2 (33.1)           | 81.8 (15.5)               | 93.9 (86)                  | 0.007   |
| Serum uric acid (μmol/L)      | 334.2 (80.4)          | 333.8 (79.0)              | 337.2 (91)                 | 0.643   |
| Triglyceride (mmol/L)         | 1.4 (0.9)             | 1.4 (0.9)                 | 1.4 (1.2)                  | 0.560   |
| High-density lipoprotein cholesterol (mmol/L) | 1.2 (0.3) | 1.2 (0.3) | 1.1 (0.3) | 0.052   |
| Low-density lipoprotein cholesterol (mmol/L) | 2.8 (0.8) | 2.9 (0.8) | 2.7 (0.9) | 0.016   |
| Apolipoprotein A1 (g/L)       | 1.3 (0.3)             | 1.3 (0.3)                 | 1.2 (0.3)                  | 0.004   |
| Apolipoprotein B (g/L)        | 0.9 (0.2)             | 0.9 (0.2)                 | 0.9 (0.2)                  | 0.164   |

Table 2. Odds ratio and 95% confidence interval of 1134 patients with prostate cancer according to the quintiles of serum creatinine.

| Serum creatinine (μmol/L) | Q1: <70.1 | Q2: 70.1-76.8 | Q3: 76.8-83.4 | Q4: 83.4-92.1 | Q5: >92.1 |
|----------------------------|-----------|---------------|---------------|---------------|-----------|
| Model                      | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Model1                     |            |              |              |              |            |
| OR                          | 3.62 (1.73, 7.56) | 3.02 (1.43, 6.39) | 3.24 (1.54, 6.80) | 3.77 (1.81, 7.83) |<0.001    |
| Model2                     |            |              |              |              |            |
| OR                          | 3.66 (1.75, 7.67) | 3.00 (1.42, 6.34) | 3.27 (1.55, 6.87) | 3.76 (1.80, 7.87) |<0.001    |
| Model3                     |            |              |              |              |            |
| OR                          | 4.67 (1.91, 12.38) | 4.62 (1.81, 11.78) | 4.25 (1.69, 10.71) | 5.46 (2.16, 13.80) |<0.001    |

**Model 1**: crude. **Model 2**: adjusted for age and BMI. **Model 3**: adjusted for age, BMI, serum albumin, alkaline phosphatase, creatine kinase isoenzyme, serum calcium, serum phosphorus, lactic dehydrogenase, low-density lipoprotein cholesterol, and apolipoprotein A1.
Discussion

Based on data from 1134 patients with prostate cancer, the main finding of this study was that serum creatinine was an independent risk factor for a high-risk prostate cancer prognosis, and the relationship showed a U-shaped curve. Patients with decreased and increased serum creatinine levels have a significantly higher prognostic risk of prostate cancer. The prognostic risk of prostate cancer was lowest when serum creatinine levels were in the range of 70.1-76.8 umol/L. In the different adjusted models, the groups were consistent with the associations obtained before adjustment.

At present, there are very few studies on the relationship between serum creatinine and the prognosis of prostate cancer. A relevant domestic study has shown that the combined detection of sarcosine levels and matrix metallopeptidase 9 has diagnostic value for prostate cancer, and sarcosine is involved in the cancerous process of the prostate [20]. Moreover, in another study involving 262 patients with prostatic diseases, it was shown that sarcosine showed an increase during prostate cancer; however, it could also reflect the degree of invasion of prostate cancer [21]. The results of a case-control study in Nigeria showed that the increase in serum urea and creatinine concentrations and the decrease in cystatin C levels can increase the risk of renal dysfunction in patients with prostate cancer [22]. These studies suggest a possible implication of serum creatinine in the prognostic risk stratification in prostate cancer. After 1134 patients with prostate cancer in the present study were adjusted for age, BMI, serum albumin, alkaline phosphatase, calcium, and other risk factors, lower or higher serum creatinine levels were significantly associated with a high-risk prostate cancer prognosis. Our findings suggest an independent predictive role of serum creatinine in prostate cancer prognosis and suggest that controlling serum creatinine concentrations in patients with prostate cancer at 70.1 to 76.8 umol/L may have positive significance for patient prognosis.

Additional studies have been on the role of creatine and sarcosine in the development of prostate cancer and the role of serum creatinine in the diagnosis of prostate cancer [23,24]. However, there are very few studies on the relationship between serum creatinine and the prognostic risk of prostate cancer, and the exact mechanism is still unclear. Therefore, based on previous studies, we proposed the following hypothesis about the mechanism of the relationship between serum creatinine and high-risk prostate cancer prognosis: Serum creatinine levels can reflect the nutritional, metabolic, and renal status of patients to some extent [25]. Clinically, a decrease in serum creatinine indicates that the patient’s total muscle mass

![Figure 2. U-shaped relationship between serum creatinine level and high-risk prostate cancer prognosis.](image)

**Table 3.** Odds ratio and 95% confidence interval of high risk of prostatic cancer according to quintiles of creatinine: subgroup analyses.

| Subgroups | Serum creatinine (umol/L) | Q1       | Q2       | Q3       | Q4       | Q5       | P-interaction |
|-----------|--------------------------|----------|----------|----------|----------|----------|--------------|
| Age, years |                          | Q1       | Q2       | Q3       | Q4       | Q5       | P-interaction |
| <67 (medium) |                          | 3.60     | 4.18     | 2.60     | 5.73     | 0.824    |              |
| BMI, kg/m² |                          | 5.81     | 5.45     | 6.39     | 6.07     | 0.129    |              |
| <24 |                          | 6.16     | 7.34     | 5.13     | 3.30     |          |              |
| ≥24 |                          | 4.31     | 3.00     | 4.16     | 6.64     |          |              |

Except for stratified variables, all variables are adjusted according to Model 3 in Table 2.
Sarcosine is the main amino acid for the synthesis of creatine and creatinine. A high concentration of sarcosine will lead to increased serum creatinine production, which also confirms the role of serum creatinine in cancer. Finally, studies have shown that blood lipids and lipoproteins are positively correlated with the high risk of prostate cancer [35]. Blood lipids are important factors affecting serum creatinine and therefore low levels of serum creatinine are mainly due to the low nutritional status of patients with prostate cancer, which affects patient prognosis [36]. High levels of serum creatinine can be involved in the conversion of nutrients and ATP in the growth of prostate tumor cells and the role of blood lipids and lipoproteins in the development of prostate cancer, resulting in an increased prevalence of prostate cancer and poor prognosis of prostate cancer patients.

Our study had limitations. First, the data of this study were obtained from a single center of the National Center for Clinical Medical Sciences (the Chinese PLA General Hospital), and the results were not as representative as those of a multicenter study. Second, we did not directly participate in the collection of study data and therefore there may be some limiting factors in the study. Third, there were some missing data on PSA results were not as representative as those of a multicenter study. Second, we did not directly participate in the collection of study data and therefore there may be some limiting factors in the study. Third, there were some missing data on PSA

and Gleason scores in the study. These patients were excluded from the data cleansing phase, which may have led to selection bias. Fourth, creatinine also reflects renal function to a degree, so preoperative renal function is an important parameter that may directly effect the prognosis of prostate cancer. In addition, prostate cancer patients with high Gleason scores can have urinary tract metastasis, which may also have had some influence on the results. Unfortunately, the dataset we requested does not have information on these 2 factors. Fifth, although confounding factors such as age and BMI were adjusted for in the multivariate model, it cannot be ruled out that other unmeasured or inadequately measured factors may have confounded the true association. Sixth, through data analysis, we concluded that the serum creatinine level has an effect on the prognostic risk of prostate cancer, but this study is a retrospective clinical observational study, and its results do not explain the causal relationship between the 2, as in longitudinal studies. Therefore, more studies are needed to provide strong evidence for the association between these 2 variables.

Conclusions

Serum creatinine levels are independently associated with a high-risk prognosis in column adenocarcinoma. The mechanism of the relationship between serum creatinine and prognosis in prostate cancer patients is still lacking strong evidence. However, our study showed that there is a U-shaped curve relationship between serum creatinine levels and the level of prostate cancer prognosis. Low or high serum creatinine levels increase the prognostic risk of prostate cancer. Controlling the serum creatinine level at 70.1 to 76.8 umol/L in patients with prostate cancer may be beneficial for their prognosis.

Acknowledgments

We gratefully thank the data provided by the National Population Health Data Center and the study patients of the Chinese PLA General Hospital.

Declaration of Figures’ Authenticity

All figures submitted have been created by the authors who confirm that the images are original with no duplication and have not been previously published in whole or in part.

References:

1. McGuire S. World cancer report 2014. Geneva, Switzerland: World Health Organization, international agency for research on cancer, WHO Press, 2015. Adv Nutr. 2016;7(2):418-19
2. Rebbeck TR. Prostate cancer genetics: Variation by race, ethnicity, and geography. Semin Radiat Oncol: 2017;27(1):3-10
3. Liu X, Yu C, Bi Y, Zhang Z. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health. 2019;172:70-80
4. Zhang S, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2015. J Natl Cancer Center. 2021;1(1):2-11

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]
5. Van Poppel H, Roobol MJ, Chapple CR, et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021. Eur Urol. 2021;80(6):703-11

6. Xu L, Wang J, Guo B, et al. Comparison of clinical and survival characteristics between prostate cancer patients of PSA-based screening and clinical diagnosis in China. Oncotarget. 2018;9(1):428

7. Tian J-X, Guo F-J, Zheng G-Y, Ahmad A. Prostate cancer: Updates on current strategies for screening, diagnosis and clinical implications of treatment modalities. Carcinogenesis. 2018;39(3):307-17

8. Costello AI. Considering the role of radical prostatectomy in 21st century prostate cancer care. Nat Rev Urol. 2020;17(3):177-88

9. Nabid A, Carrier N, Martin A-G, et al. Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized phase III trial. Eur Urol. 2018;74(4):432-41

10. Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119-34

11. Schaeffer E, Srivivas S, Antonarakis ES, et al. NCCN guidelines insights: Prostate cancer, version 1.2021.2021: Updated features to the NCCN guidelines. J Natl Compr Canc Netw. 2021;19(2):134-43

12. Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141(12):929-37

13. Weinstein SJ, Mackain K, Stolzenberg-Solomon RZ, et al. Serum creatinine level in patients with vulvar cancer. Sci Rep. 2019;9(1):11129

14. Malyyszko J, Tesarova P, Capasso G, Capasso A. The link between kidney disease and cancer: Complications and treatment. Lancet. 2020;396(10246):277-87

15. Parker C, Castro E, Fizazi K, et al: Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119-34

16. Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141(12):929-37

17. Weinstein SJ, Mackain K, Stolzenberg-Solomon RZ, et al. Serum creatinine level in patients with vulvar cancer. Sci Rep. 2019;9(1):11129

18. Malyyszko J, Tesarova P, Capasso G, Capasso A. The link between kidney disease and cancer: Complications and treatment. Lancet. 2020;396(10246):277-87

19. Schwameis R, Postl M, Bekos C, et al. Prognostic value of serum creatine level in patients with vulvar cancer. Sci Rep. 2019;9(1):11129

20. Han H, Zhan Z, Xu J, Song Z. TIMP2 inhibits pancreatic cancer cells proliferation, migration, and invasion by suppressing phosphorylation of the MAPK signaling pathway. Onco Targets Ther. 2019;12:13371

21. Narwal V, Kumar P, Joon P, Pundir C. Fabrication of an amperometric sarcosine biosensor based on sarcosine oxidase/chitosan/CuNPs/c-MWCNT/Au electrode for detection of prostate cancer. Enzyme Microb Technol. 2018;113:44-51

22. Oluboyo A, Adeleke A, Oluboyo B. Evaluation of selected renal markers in prostate cancer. J Appl Sci and Environ Manag. 2019;23(9):1725-28

23. Amamoto R, Uchiimi T, Yagi M, et al. The expression of ubiquitous mitochondrial creatine kinase is downregulated as prostate cancer progression. J Cancer. 2016;7(1):50

24. Cermei N, Heger Z, Gumblec J, et al: Sarcosine as a potential prostate cancer biomarker—a review. Int J Mol Sci. 2013;14(7):13893-908

25. Pupim LB, Cuppari L, Kizier TA. Nutrition and metabolism in kidney disease. Semin Nephrol. 2006;26(2):134-57

26. Heimbürger O, Quareshi AR, Blaner WS, et al. Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. Am J Kidney Dis. 2000;36(6):1213-25

27. Kashani K, Rosner MH, Ostermann M. Creatinine: From physiology to clinical application. Eur J Intern Med. 2020;72:9-14

28. Braun J-P, Lefebvre H, Watson A. Creatinine in the dog: A review. Vet Clin Oncol Hematol. 2010;73(1):68-91

29. Hall JC. Nutritional assessment of surgery patients. J Am Coll Surg. 2018;202(5):836-855

30. Braun J-P, Lefebvre H, Watson A. Creatinine in the dog: A review. Vet Clin Oncol Hematol. 2010;73(1):68-91

31. Bergers G, Fentd S-M. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021; 21(3):162-80

32. Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, et al. Cancer metabolism: A therapeutic perspective. Nat Rev Clin Oncol. 2017;14(1):11-31

33. de Andrade RB, Gemelli T, Rojas DB, et al. Evaluation of oxidative stress parameters and energy metabolism in cerebral cortex of rats subjected to sarcosine administration. Mol Neurobiol. 2017;54(6):4996-5006

34. Petersen LE, Brockton NT, Bakkar A, et al. Elevated physiological levels of folic acid can increase in vitro growth and invasiveness of prostate cancer cells. BIU Int. 2012;109(5):788-95

35. Alloz EH, Howard LE, Cooperberg MR, et al. Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2349-56

36. Droz J-P, Balducci L, Bolla M, et al. Background for the proposal of SIOP guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol. 2010;73(1):68-91